Company / Cost of Revenue
United Therapeutics Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$384.4M
FY2025
5-year range
$122.5M / $384.4M
FY2021-FY2025
Trend
+24.1%
vs FY2024
Sector context
#25 of 85
Health Care
What the data says
At $384M, United Therapeutics's cost of revenue ranks #61 of 85 in the Health Care sector. Cost of Revenue has increased for 5 consecutive years, from $108M in FY2020 to $384M in FY2025.
Based on SEC 10-K filings.
$384M in FY2025 with a 5-year CAGR of +28.9%.
Increased from $258M to $384M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +36.4%
- 5-Year CAGR
- +28.9%
- 10-Year CAGR
- -
Sector benchmark
#61 of 85 in Health CareTop 71% of 85This company $384.4M Sector average $2.0B
▼
-80.6% below sector average
Key checks
Key Insights
- United Therapeutics's cost of revenue has grown for 5 consecutive years.
- 5-year CAGR of +28.9%, indicating consistent growth.
- In FY2025, cost of revenue increased 24.1% year-over-year.
- Ranks #25 out of 85 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 6.00 (safe zone, above 2.9 threshold)
- Strong profit margin: 40.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $384.4M | +24.1% |
| FY2024 | $309.7M | +20.3% |
| FY2023 | $257.5M | +69.9% |
| FY2022 | $151.6M | +23.8% |
| FY2021 | $122.5M | +13.3% |
| FY2020 | $108.1M | -8.1% |
| FY2019 | $117.6M | -40.8% |
| FY2018 | $198.7M | +188.0% |
| FY2017 | $69.0M | -5.1% |
| FY2016 | $72.7M | +5.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026